Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia
Background: The present study investigated the patients with Chronic Myeloid Leukemia in chronic phase (CP-CML) who had beenon the first- line Imatinib Mesylate (IM) therapy for a period of 84 months. Materials and Methods: This retrospective study was conducted in 295 newly-diagnosed CP-CML patient...
Main Authors: | Ladan Nekoohesh, Mohammad H. Ghahremani, Shahrbanoo Rostami, Mohsen Nikbakht, Leila Nekoohesh, Roozbeh Naemi, Saeed Mohammadi, Laya Ghadyaninejad, Seyed Asadollah Mousavi, Mohammad Vaezi, Kamran Alimoghaddam, Bahram Chahardouli |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2020-01-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1244 |
Similar Items
-
Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01) -
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01) -
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01) -
Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01) -
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
by: Smeeta GAJENDRA, et al.
Published: (2019-01-01)